Biotech Startups

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells. It focuses on treatments for antibody-mediated organ transplant rejection and autoimmune diseases such as immune thrombocytopenia.

1 investor

Castarunion (国科星联) is a synthetic biology company that manufactures human-sourced functional proteins, particularly lactoferrin and other glycoproteins, using precision fermentation and gene editing technology. The company serves food and nutrition companies seeking bioactive protein ingredients with enhanced health benefits and sustainable production methods.

1 investor

Castle Rock Biofuels produces renewable fuels from biomass feedstocks for transportation and energy markets.

1 investor

Castle's Labs sells branded agricultural and gardening products, including Manure Magic and Plant Magic, marketed to consumers for lawn and plant care.

1 investor

San Francisco company developing engineered proteases as a new class of protein therapeutics, based on technology licensed from UCSF.

1 investor

A contract research organization (CRO) that provides clinical trial and regulatory services to pharmaceutical sponsors. Catawba Research leverages scientific and regulatory expertise to support drug development programs across multiple therapeutic areas.

1 investor

Latch Medical develops microneedle-based intradermal injection devices for both healthcare professional and patient self-administration of vaccines and therapeutics. Marketed to the pharmaceutical industry, its devices support drug delivery from pre-clinical testing through clinical use.

1 investor

CatSci is a contract research organization (CRO) providing drug development services — including catalyst screening, process chemistry, analytical development, oligonucleotides, peptides, and bioscience — to help biotech and pharma companies advance complex synthetic medicines from discovery to IND. It operates 14 laboratories across the UK and Europe and serves more than 100 biotech and global pharma customers.

1 investor

Cavendish operates a peer-to-peer community connecting health and life sciences innovators with family offices, foundations, philanthropists, and impact investors to fund projects between proof-of-concept and commercialization. It offers forums and summits, a digital community, advisory services, and access to experts and capital sources focused on impact investing and sustainable philanthropy.

1 investor

Cavigen develops 3D cell culture technology that standardizes organoid formation in defined microcavities and supports oxygen-sensing to better mimic tissue-like oxygen conditions. It targets researchers running 3D cell culture and drug testing workflows, working alongside existing laboratory instruments.

1 investor

Cbio develops next-generation T-cell therapies for solid tumors, which account for the majority of cancers. Its lead product, novoleucel, is a minimally invasive cell therapy designed to improve clinical outcomes and survival for late-stage cancer patients.

1 investor

CBSET is a preclinical translational research institute that provides GLP-compliant, AAALAC-accredited contract research services—including vivaria, imaging labs, surgical suites, histopathology, and pathology—for medical device, pharmaceutical, and academic sponsors. It supports clients' regulatory filings and product development from its facilities in the greater Boston area.

1 investor

CC Bio develops synthetic biology-based therapeutics to treat microbiome-related diseases by engineering and editing the microbiome with precision. The company uses its proprietary Zeus platform to discover and optimize first-in-class treatments for patients seeking alternatives to antibiotics.

1 investor

This site publishes articles about regulatory affairs for immunotherapy, covering topics such as EMA approval processes, orphan drug designation, biomarkers, clinical trials, and compliance in manufacturing. It appears to be a content/blog resource rather than a product company.

1 investor

Cebina is an early-stage biotech investor and incubator that funds and de-risks pre-company and startup drug development projects across pre-seed, seed, and Series A stages. It focuses on therapeutic areas including cardiovascular and metabolic diseases, lung fibrosis, cancer immunotherapy, and anti-infectives, and also pursues co-development and licensing partnerships.</parameter> <parameter name="founders">[]

1 investor

Cedar Health Research operates clinical research services for community-based healthcare providers, connecting patient populations with clinical trials through partnerships and EMR abstraction technology. The company aims to ensure clinical trial participants reflect the broader patient population bearing disease burden.

1 investor

Celestial Therapeutics is a biotech company whose team works across genetics, virology, bioengineering, pulmonary surfactant lipid and protein chemistry, innate immunity, infectious diseases, and pharmacology. The available page provides only background on the founders' and team's expertise, without detailing specific products.

1 investor

Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.

1 investor

A Korean company presenting itself as a global partner focused on quality and innovative technology, with sections describing its company overview, history, and business locations. The website provides insufficient detail to determine the specific products, services, or industry it operates in.

1 investor

The page is an online gambling/gaming platform (branded "LUXURY333") promoting casino-style games, togel/toto betting, bonuses, and 24-hour customer support. Despite the domain cellidx.com, the content is unrelated gambling promotional material, not a legitimate company profile.

1 investor

Cell Invent develops human disease models using reprogrammed Alzheimer patient cells to identify new therapeutic approaches for Alzheimer's disease. The company applies proprietary cellular research technology from Lund University to drug discovery and disease modeling for the neurodegenerative disease market.

1 investor

Cell Reserves Inc. is a biotechnology company developing a molecular shield platform technology to increase the bio-availability and persistence of bio-therapeutics in circulation. Its pipeline focuses on treatments for autoimmune diseases such as myasthenia gravis, pemphigus, and thyroid eye disease, using proprietary ligands targeting a regulatory receptor.

1 investor

CellaraRx develops Horizen, a platform that uses single-cell RNA sequencing, digital pathology, and AI to help clinicians and drug developers predict patient response to cancer treatments before clinical trial enrollment. The platform identifies tumor resistance mechanisms and tissue drug accessibility to improve patient stratification and trial success rates.

1 investor

Cellarim produces beauty and skincare ingredients using enzymatic, cell-free synthesis rather than extraction, fermentation, or conventional chemical methods. It positions its enzyme-based approach as a way to make purer, more scalable, and more sustainable cosmetic ingredients.

1 investor